Security Snapshot

UNITED THERAPEUTICS Corp - Common Stock, par value $.01 per share (UTHR) Institutional Ownership

CUSIP: 91307C102

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

536

Shares (Excl. Options)

19.28MFull value: 19,280,230 · shares · 30 Sep 2026

Price

$541.89

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, par value $.01 per share
Symbol
UTHR on Nasdaq
All holders as of 30 Sep 2026
Q3 2026
Total 13F shares
19,280,230
Latest holder snapshot 5 signals
Total 13F value
$10,439,957,423
Portfolio coverage rank
0.01%
Share change
+1,270,554
Value change
+$674,514,924
Number of holders
536
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
43,143,025
SEC-reported price per share
$532.78
Insider filing price
$532.78
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • UTHR - UNITED THERAPEUTICS Corp - Common Stock, par value $.01 per share is tracked under CUSIP 91307C102.
  • 536 institutions reported positions in Q3 2026.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 884 to 536 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $22.63BFull value: $22,628,735,138 · USD · 30 Jun 2026
    to
    $10.44BFull value: $10,439,957,423 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 536 institutions filings for Q3 2026.

Open SEC evidence

Security key

91307C102

13F reference period

Q3 2026

13F holders

536

13D/G owners

4

CIK / CUSIP context first

Open Q3 2026 holders UTHR full holder history UNITED THERAPEUTICS Corp SEC filings UNITED THERAPEUTICS Corp company facts UNITED THERAPEUTICS Corp insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
4
Security
UTHR
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD CAPITAL MANAGEMENT LLC 5.2% $1,351,014,797 2,278,348 Vanguard Capital Management 31 Mar 2026
STATE STREET CORP 4.9% $661,670,195 2,199,994 STATE STREET CORPORATION 31 Dec 2024
ROTHBLATT MARTINE A 4% -26% $919,429,634 -$323,930,240 1,725,721 -26% Martine A. Rothblatt 30 Sep 2026
WELLINGTON MANAGEMENT GROUP LLP 3.2% -42% $764,448,718 -$588,967,957 1,379,025 -44% Wellington Management Group LLP 30 Jun 2026
As of 30 Sep 2026, 536 institutional investors reported holding
19.28MFull value: 19,280,230 · shares · 30 Sep 2026
shares of UNITED THERAPEUTICS Corp - Common Stock, par value $.01 per share (UTHR). This represents 45% of the company’s total
43.14MFull value: 43,143,025 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
35%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
STATE STREET CORP 4.5% 1,952,557 +2.9% 0.03% $1,058,071,113
VANGUARD CAPITAL MANAGEMENT LLC 4.5% 1,928,928 +0.56% 0.02% $1,045,266,794
VANGUARD PORTFOLIO MANAGEMENT LLC 4.4% 1,911,530 -0.41% 0.05% $1,035,838,992
RENAISSANCE TECHNOLOGIES LLC 3.9% 1,675,899 -1.9% 1.2% $908,152,909
Amundi 2.3% 988,820 +351% 0.12% $535,831,670
GEODE CAPITAL MANAGEMENT, LLC 2.3% 974,993 -2.2% 0.03% $527,238,922
Invesco Ltd. 1.9% 806,324 +70% 0.03% $436,938,912
ASSETMARK, INC 1.4% 600,171 -3.8% 0.55% $325,226,756
DIMENSIONAL FUND ADVISORS LP 1.3% 540,877 +2.5% 0.05% $292,859,738
MORGAN STANLEY 1% 444,199 +1.7% 0.01% $240,707,925
Swedbank AB 0.95% 408,025 +26% 0.19% $221,104,668
BAILLIE GIFFORD & CO 0.88% 379,095 -19% 0.19% $205,427,790
FIRST TRUST ADVISORS LP 0.81% 349,666 +40% 0.11% $189,480,498
VANGUARD FIDUCIARY TRUST CO 0.63% 271,584 +1.2% 0.03% $147,168,654
Pictet Asset Management Holding SA 0.55% 235,721 -12% 0.12% $127,073,495
TD ASSET MANAGEMENT INC 0.51% 221,920 +32% 0.09% $106,847,822
Epoch Investment Partners, Inc. 0.47% 204,552 +36% 0.66% $110,844,683
FRANKLIN TEMPLETON INC 0.47% 201,950 -41% 0.03% $122,884,556
DEUTSCHE BANK AG\ 0.39% 166,277 -15% 0.02% $90,103,845
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 0.37% 157,474 +88% 0.04% $85,333,586
FULLER & THALER ASSET MANAGEMENT, INC. 0.34% 148,408 -33% 0.24% $80,420,559
Robeco Institutional Asset Management B.V. 0.34% 146,163 +19% 0.1% $79,204,267
Qube Research & Technologies Ltd 0.32% 136,832 -41% 0.07% $74,147,892
AustralianSuper Pty Ltd 0.29% 126,127 +41% 0.28% $68,346,960
CAPITAL FUND MANAGEMENT S.A. 0.26% 110,907 +109% 0.37% $60,099,394

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
51
Headline period
Q3 2026
Rows shown
1-25 of 51
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 19,280,230 $10,439,957,423 +$674,514,924 $541.89 536
2026 Q2 41,729,983 $22,628,735,138 +$139,295,591 $541.83 884
2026 Q1 41,506,194 $24,574,371,128 -$38,155,881 $592.98 855
2025 Q4 41,674,368 $20,284,637,524 +$459,092,354 $487.25 832
2025 Q3 40,884,780 $17,141,521,441 -$1,065,484,238 $419.21 701
2025 Q2 43,924,518 $12,621,620,981 -$132,393,705 $287.35 662
2025 Q1 44,441,020 $13,691,236,526 +$58,445,640 $308.27 661
2024 Q4 43,992,356 $15,526,430,783 +$60,965,879 $352.84 667
2024 Q3 43,520,361 $15,594,079,368 -$719,584,018 $358.35 617
2024 Q2 45,751,455 $14,568,456,882 +$331,436,428 $318.55 557
2024 Q1 45,081,525 $10,361,695,587 +$141,369,039 $229.72 518
2023 Q4 44,516,671 $9,786,687,446 +$24,490,915 $219.89 528
2023 Q3 44,424,001 $10,034,347,626 -$137,617,629 $225.87 503
2023 Q2 44,929,853 $9,916,555,660 -$53,987,464 $220.75 466
2023 Q1 45,106,269 $10,099,164,591 -$14,220,192 $223.96 499
2022 Q4 44,906,712 $12,485,251,712 +$52,130,518 $278.09 506
2022 Q3 44,754,285 $9,370,900,072 +$62,537,202 $209.38 450
2022 Q2 44,045,171 $10,378,944,055 +$127,464,630 $235.64 462
2022 Q1 44,003,492 $7,893,754,591 +$134,402,123 $179.41 416
2021 Q4 43,119,761 $9,315,950,531 -$262,053,365 $216.08 409
2021 Q3 44,131,602 $8,148,234,087 +$112,030,536 $184.58 415
2021 Q2 43,453,740 $7,794,694,945 +$9,014,738 $179.41 397
2021 Q1 43,411,843 $7,268,500,823 +$26,763,473 $167.27 384
2020 Q4 43,003,015 $6,528,125,218 +$196,460,628 $151.79 347
2020 Q3 41,894,495 $4,231,829,902 -$29,144,918 $101.00 320
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .